• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Tracing a Five-Generation Cancer Legacy Through Genetic Discovery

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease myself. Read More

Patritumab Deruxtecan BLA Withdrawn in Non-Small Cell Lung Cancer

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in the U.S. has been withdrawn. Read More

FDA Grants Priority Review to Sevabertinib NDA in HER2+ Lung Cancer

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer. Read More

Personalizing Prostate Cancer Care With Genetic Testing, PARP Inhibitors

by MM360 Staff | May 29, 2025 | Uncategorized

Source: CureToday articles Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining treatment with PARP inhibitors. Read More

Expanding Access to Screening May Help Prevent Esophageal Cancer

by MM360 Staff | May 28, 2025 | Uncategorized

Source: CureToday articles Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer. Read More

HT-KIT Shows Activity in Rare KIT-Driven Cancers, Preclinical Data Finds

by MM360 Staff | May 28, 2025 | Uncategorized

Source: CureToday articles Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, including GIST and some leukemias. Read More
« Older Entries
Next Entries »

Recent Content

  • MRD Monitoring May Help Redefine Long-Term Goals in Myeloma Therapy
  • Day 3: Top Takeaways From ASCO25
  • NLA 2025: The Earlier LDL Cholesterol Is Lowered, the Greater the Cardiovascular Risk Reduction
  • NLA 2025: Emerging Therapies Target Remnant Cholesterol to Address Residual Cardiovascular Risk
  • NLA 2025: Practical Strategies for Identifying the Right Patient for Incretin Therapy
  • Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer
  • Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups
  • Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer
  • NLA 2025: Understanding the Impact of Omega-3 Fatty Acids on LDL Cholesterol
  • Harnessing the Tumor Microenvironment for Enhanced Cancer Treatment
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT